Fatty Acid-Binding Proteins 4 and 5 Are Involved in the Pathogenesis of Retinal Vascular Diseases in Different Manners.
fatty acid-binding protein 5 (FABP5)
fatty-binding protein 4 (FABP4)
proliferative diabetic retinopathy (PDR)
retinal vascular disease (RVD)
retinal vein occlusion (RVO)
vascular endothelial growth factor A (VEGFA)
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
23 Mar 2022
23 Mar 2022
Historique:
received:
03
03
2022
revised:
21
03
2022
accepted:
21
03
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
This study reports on the pathological significance of the vitreous fatty acid-binding protein (Vt-FABP) 4 and 5, and vascular endothelial growth factor A (Vt-VEGFA) in patients with retinal vascular diseases (RVDs) including proliferative diabetic retinopathy (PDR) and retinal vein occlusion (RVO). Subjects with PDR (n = 20), RVO (n = 10), and controls (epiretinal membrane, n = 18) who had undergone vitrectomies were enrolled in this study. The levels of Vt-FABP4, Vt-FABP5, and Vt-VEGFA were evaluated by enzyme-linked immunosorbent assays (ELISA). Retinal circulation levels were measured by a laser-speckle flow analyzer (LSFA) and other relevant data were collected. The Vt-FABP5 levels were significantly (p < 0.05) elevated in patients with RVDs compared to control patients. This elevation was more evident in patients with RVO than with PDR. Log Vt-FABP5 was significantly correlated negatively or positively with all the LSFA retinal circulation indexes or Log triglycerides (r = 0.31, p = 0.031), respectively. However, the elevations in the Vt-FABP4 and Vt-VEGFA levels were more evident in the PDR group (p < 0.05) and these factors were correlated positively with Log fasting glucose and negatively with some of the LSFA retinal circulation indexes. Multivariable regression analyses indicated that the LSFA blood flows of the optic disc at baseline was an independent effector with Log Vt-FABP5 other than several possible factors including age, gender, Log triglycerides, Log Vt-FABP4 and Log Vt-VEGFA. These current findings suggest that Vt-FABP5 is involved in the pathogenesis of RVD in a manner that is different from that for Vt-FABP4 and Vt-VEGFA, presumably by regulating retinal circulation.
Identifiants
pubmed: 35454958
pii: life12040467
doi: 10.3390/life12040467
pmc: PMC9025502
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Prim Care. 2015 Sep;42(3):451-64
pubmed: 26319349
PLoS One. 2016 Apr 28;11(4):e0153817
pubmed: 27123642
Fluids Barriers CNS. 2013 Oct 02;10(1):29
pubmed: 24083450
J Neurochem. 2011 May;117(4):735-46
pubmed: 21395585
Am J Hypertens. 2012 Oct;25(10):1124-30
pubmed: 22717543
Acta Ophthalmol. 2010 Nov;88(7):723-9
pubmed: 19725814
Int J Mol Sci. 2018 Nov 04;19(11):
pubmed: 30400384
Eur Heart J. 2008 Sep;29(17):2156-63
pubmed: 18603624
J Glob Health. 2019 Jun;9(1):010427
pubmed: 31131101
Angiogenesis. 2012 Sep;15(3):457-68
pubmed: 22562362
J Diabetes Investig. 2019 Jul;10(4):1059-1067
pubmed: 30516339
Nat Rev Drug Discov. 2008 Jun;7(6):489-503
pubmed: 18511927
Biochemistry. 1998 Mar 10;37(10):3250-7
pubmed: 9521644
Cell Metab. 2005 Feb;1(2):107-19
pubmed: 16054052
Retina. 2018 Aug;38(8):1581-1587
pubmed: 28614133
Nat Rev Endocrinol. 2015 Oct;11(10):592-605
pubmed: 26260145
J Am Heart Assoc. 2017 Sep 13;6(9):
pubmed: 28903937
Oncogene. 2003 May 8;22(18):2739-49
pubmed: 12743598
Ophthalmology. 1990 Nov;97(11):1543-8
pubmed: 2255527
Science. 1996 Nov 22;274(5291):1377-9
pubmed: 8910278
Diabetes. 2003 Feb;52(2):300-7
pubmed: 12540600
PLoS One. 2013 Nov 20;8(11):e81318
pubmed: 24278421
PLoS One. 2021 Jan 27;16(1):e0245763
pubmed: 33503066
Dev Ophthalmol. 2017;58:139-167
pubmed: 28351046
Retina. 1981;1(1):27-55
pubmed: 15633406
Retina. 2015 Oct;35(10):2037-42
pubmed: 25932555
FASEB J. 2009 Nov;23(11):3865-73
pubmed: 19625659
Acta Ophthalmol. 2015 Dec;93(8):e649-53
pubmed: 25899144
Arterioscler Thromb Vasc Biol. 2007 Aug;27(8):1796-802
pubmed: 17510463
Nat Med. 2001 Jun;7(6):699-705
pubmed: 11385507
Oncotarget. 2016 Feb 23;7(8):9322-39
pubmed: 26814431
J Vasc Res. 2010;47(4):287-98
pubmed: 20016203
J Lipid Res. 2008 Aug;49(8):1746-51
pubmed: 18421072
Mol Pharm. 2015 Dec 7;12(12):4375-85
pubmed: 26455443
Ophthalmology. 2017 Dec;124(12):1778-1787
pubmed: 28807635
Retina. 2017 Feb;37(2):334-343
pubmed: 27429384
Ophthalmology. 2016 Feb;123(2):330-336
pubmed: 26522708
PLoS One. 2018 Sep 20;13(9):e0204015
pubmed: 30235264
Clin Chem. 2006 Mar;52(3):405-13
pubmed: 16423904
Diabetes Metab. 2019 Dec;45(6):517-527
pubmed: 31005756
Ophthalmology. 2010 Feb;117(2):313-9.e1
pubmed: 20022117
Curr Med Chem. 2020;27(22):3657-3664
pubmed: 30306857
Am J Cardiol. 2010 Oct 15;106(8):1118-23
pubmed: 20920650
Ophthalmology. 2010 Jun;117(6):1102-1112.e1
pubmed: 20398941
Ophthalmology. 2018 May;125(5):691-700
pubmed: 29395119
J Endocrinol. 2017 Jun;233(3):R173-R184
pubmed: 28420707
Arch Ophthalmol. 2003 Feb;121(2):225-31
pubmed: 12583789
Ophthalmology. 2014 Mar;121(3):637-42
pubmed: 24053999
J Atheroscler Thromb. 2019 Mar 1;26(3):216-232
pubmed: 30726793
BMJ Open Ophthalmol. 2019 Dec 10;4(1):e000390
pubmed: 31909195
J Clin Invest. 2008 Jul;118(7):2640-50
pubmed: 18551191
Arterioscler Thromb Vasc Biol. 2011 Jun;31(6):1283-90
pubmed: 21474828
Sci Rep. 2021 Jun 11;11(1):12382
pubmed: 34117325